TYMS and colorectal cancer: In preclinical studies using colorectal cancer cells, OHP has been combined with a variety of anticancer metabolites to improve its killing efficacy, such as TS inhibitors (Raymond et al, 1997), taxanes and topoisomerase I inhibitors (Raymond et al, 1998a; Raymond et al, 2002).